How have NTRB shares performed in 2023?

Nutriband's stock was trading at $3.6048 on January 1st, 2023. Since then, NTRB shares have decreased by 30.6% and is now trading at $2.50. View the best growth stocks for 2023 here .

When is Nutriband's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, December 8th 2023. View our NTRB earnings forecast .

How were Nutriband's earnings last quarter?

Nutriband Inc. (NASDAQ:NTRB) announced its earnings results on Monday, September, 11th. The company reported ($0.11) earnings per share (EPS) for the quarter. The firm had revenue of $0.66 million for the quarter. Nutriband had a negative trailing twelve-month return on equity of 55.88% and a negative net margin of 201.80%.

When did Nutriband's stock split?

Shares of Nutriband split before market open on Monday, August 15th 2022. The 13-6 split was announced on Monday, August 15th 2022. The newly minted shares were issued to shareholders after the closing bell on Monday, August 15th 2022. An investor that had 100 shares of stock prior to the split would have 217 shares after the split.

How do I buy shares of Nutriband?

Shares of NTRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Nutriband Stock Price, News & Analysis (NASDAQ:NTRB)

$2.50

+0.05 (+2.04%)

(As of 04:37 PM ET)

Compare

Today's Range: $2.44
▼
$2.50
50-Day Range: $1.89
▼
$2.72
52-Week Range: $1.53
▼
$5.15

Volume: 8,102 shs
Average Volume: 22,181 shs
Market Capitalization: $19.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Nutriband Stock (NASDAQ:NTRB)

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

NTRB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NTRB Stock News Headlines

November 29, 2023 | americanbankingnews.com

Nutriband (NASDAQ:NTRB) Stock Price Down 7.7%

November 28, 2023 | finance.yahoo.com

Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling

December 8, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.

November 28, 2023 | finance.yahoo.com

Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling

October 11, 2023 | finance.yahoo.com

Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales of $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm

September 20, 2023 | finanznachrichten.de

Financialnewsmedia.com: Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise

September 20, 2023 | finanznachrichten.de

Nutriband Inc.: Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology

September 20, 2023 | finance.yahoo.com

Nutriband Unveils Groundbreaking Innovation in Transdermal Medications

December 8, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

September 20, 2023 | finance.yahoo.com

Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology

September 12, 2023 | finance.yahoo.com

Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023

September 11, 2023 | finance.yahoo.com

Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

August 30, 2023 | finance.yahoo.com

Nutriband Inc. Announces Donovan McNabb as AI Tape Brand Ambassador

July 28, 2023 | marketwatch.com

Nutriband Shares Rise 16% After Launch of New Medical Tape Product

July 27, 2023 | finance.yahoo.com

Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings

July 14, 2023 | finanznachrichten.de

Nutriband Inc.: Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA Platform Towards FDA Submission

July 14, 2023 | marketwatch.com

Nutriband Shares Rise 14% After Credit Line Increased to Fund Fentanyl Deterrent Tech

July 14, 2023 | finance.yahoo.com

Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA Submission

June 23, 2023 | finance.yahoo.com

Nutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent Technology

May 10, 2023 | finanznachrichten.de

Nutriband Inc.: Nutriband to Attend 2023 BIO International Convention

May 10, 2023 | finance.yahoo.com

Nutriband to Attend 2023 BIO International Convention

May 4, 2023 | msn.com

Nutriband Earnings Perspective: Return On Capital Employed

April 29, 2023 | finance.yahoo.com

Nutriband Full Year 2023 Earnings: Misses Expectations

April 27, 2023 | finance.yahoo.com

Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023

April 19, 2023 | finance.yahoo.com

Nutriband Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023

April 4, 2023 | finance.yahoo.com

Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Scale Manufacturing Process Development

March 28, 2023 | finance.yahoo.com

Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology

See More Headlines

Receive NTRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nutriband and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 9/11/2023
Today: 12/08/2023
Next Earnings (Estimated): 12/08/2023
Fiscal Year End: 1/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical appliances & supplies
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NTRB
CUSIP: N/A
CIK: 1676047
Web: nutriband.com
Phone: (407) 377-6695
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,480,000.00
Net Margins: -201.80%
Pretax Margin: -201.76%
Return on Equity: -55.88%
Return on Assets: -47.56%

Debt

Debt-to-Equity Ratio: 0.30
Current Ratio: 3.75
Quick Ratio: 3.57

Sales & Book Value

Annual Sales: $2.28 million
Price / Sales: 8.59
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.09 per share
Price / Book: 2.29

Miscellaneous

Outstanding Shares: 7,833,000
Free Float: 4,682,000
Market Cap: $19.58 million
Optionable: Not Optionable
Beta: 0.79

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Serguei Melnik (Age 49)
Founder, President, Company Secretary & Executive Chairman of the Board
Comp: $200k
Mr. Gareth Sheridan (Age 33)
Founder, CEO & Director
Comp: $200k
Mr. Gerald Goodman (Age 75)
CFO & Chief Accounting Officer
Comp: $160k
Dr. Alan Smith Ph.D. (Age 57)
COO & President of 4P Therapeutics
Comp: $179k
Mr. Patrick Ryan (Age 37)
Chief Technical Officer
Dr. Jeffrey Patrick Pharm.D. (Age 53)
Chief Scientific Officer
Mr. Tyler Overk (Age 39)
President of Active Intelligence

Key Competitors

View All Competitors

NTRB Stock Analysis - Frequently Asked Questions

How have NTRB shares performed in 2023?: Nutriband's stock was trading at $3.6048 on January 1st, 2023. Since then, NTRB shares have decreased by 30.6% and is now trading at $2.50.
View the best growth stocks for 2023 here.
When is Nutriband's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, December 8th 2023.
View our NTRB earnings forecast.
How were Nutriband's earnings last quarter?: Nutriband Inc. (NASDAQ:NTRB) announced its earnings results on Monday, September, 11th. The company reported ($0.11) earnings per share (EPS) for the quarter. The firm had revenue of $0.66 million for the quarter. Nutriband had a negative trailing twelve-month return on equity of 55.88% and a negative net margin of 201.80%.

When did Nutriband's stock split?: Shares of Nutriband split before market open on Monday, August 15th 2022. The 13-6 split was announced on Monday, August 15th 2022. The newly minted shares were issued to shareholders after the closing bell on Monday, August 15th 2022. An investor that had 100 shares of stock prior to the split would have 217 shares after the split.
How do I buy shares of Nutriband?: Shares of NTRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NTRB) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial